MEDICAL DEVICE
OUR PRODUCTS
| Category | Description |
| Product | ADDNOX® |
| Indication | Reduction of ADHD symptoms |
| Target Population | Children aged 7–12 years |
| Components | Device and Base Station |
| Classification | Medical Device |
| Commercial Status | Planned launch in the United States |
ADDNOX® is a non-invasive electroceutical medical device developed to help alleviate symptoms associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in children. The system consists of a wearable stimulation device and a base station used for device management and treatment administration.
| Category | Description |
| Product | ADDNOX® |
| Indication | Reduction of ADHD symptoms |
| Target | Children aged 7-12 years |
| Components | Device and Base Station |
| Classification | Medical Device |
| Commercial Status | Planned launch in the United States |
ADDNOX® is a non-invasive electroceutical medical device developed to help alleviate symptoms associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in children. The system consists of a wearable stimulation device and a base station used for device management and treatment administration.
| Category | Description |
| Product | SMILE® |
| Indication | Reduction of ADHD symptoms |
| Target Population | Children aged 7–12 years |
| Components | Device and Base Station |
| Classification | Medical Device |
| Commercial Status | Currently marketed in China |
SMILE® is Nu Eyne's ADHD treatment device currently commercialized in the Chinese market. The system utilizes Nu Eyne's proprietary non-invasive neurostimulation technology to support the management of ADHD symptoms in pediatric patients.
| Category | Description |
| Product | SMILE® |
| Indication | Reduction of ADHD symptoms |
| Target | Children aged 7-12 years |
| Components | Device and Base Station |
| Classification | Medical Device |
| Commercial Status | Currently marketed in China |
SMILE® is Nu Eyne's ADHD treatment device currently commercialized in the Chinese market. The system utilizes Nu Eyne's proprietary non-invasive neurostimulation technology to support the management of ADHD symptoms in pediatric patients.
| Category | Description |
| Product | ELEXIR® |
| Indication | Chronic Migraine Treatment and Prevention |
| Target Population | All Ages |
| Components | Device |
| Classification | Medical Device |
| Commercial Status | Currently marketed in South Korea, Vietnam, Thailand, Singapore, India |
ELEXIR® is Nu Eyne’s Migraine treatment device currently commercialized in 5 different countries. The system utilizes Nu Eyne's proprietary non-invasive neurostimulation technology to support the management of chronic migraine.
| Category | Description |
| Product | ELEXIR® |
| Indication | Chronic Migraine Treatment and Prevention |
| Target | All Ages |
| Components | Device |
| Classification | Medical Device |
| Commercial Status | Currently marketed in South Korea, Vietnam, Thailand, Singapore, India |
ELEXIR® is Nu Eyne’s Migraine treatment device currently commercialized in 5 different countries. The system utilizes Nu Eyne's proprietary non-invasive neurostimulation technology to support the management of chronic migraine.
